

S & P 500 (/index/s&p_500) <b>7.68</b> 3,003.50 (0.26%)	NASDAQ 100 (/index/nasdaq_100) <b>21.49</b> 7,879.18 (0.27%)	DJIA (/index/dow_jones) <b>201.00</b> 26,998.00 (0.75%) 03:59:27 PM EDT	NIKKEI 225 (/index/nikkei_225) <b>-58.00</b> 21,687.00 (-0.27%)
--	---	--	--

## Cedrus' Head of Life Sciences, Ms. Kimberly Nearing, invited to moderate a panel at 2019 SAPA Healthcare Investment Forum & Roadshow in New York City

PRESS RELEASE PR Newswire

Jun. 24, 2019, 09:00 PM

HONG KONG, June 25, 2019 /PRNewswire/ -- Ms. Kimberly Nearing, Head of Life Sciences at **Cedrus Investments** ("Cedrus"), was invited to moderate a panel at the 2019 SAPA Healthcare Investment Forum & Roadshow at Columbia University in New York City on 15<sup>th</sup> June 2019.

The Sino-American Pharmaceutical Professionals Association (SAPA), established in 1993 as a non-profit organization registered in the U.S., is one of the most active professional associations in the country with seven chapters (New England, Greater Philadelphia, Connecticut, Washington DC, Chicago, San Francisco, and China) and more than 6,000 members. SAPA's members, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production, are primarily affiliated with large and mid-sized pharmaceutical and biotechnology companies in the U.S. In service to the advancement of pharmaceutical science and biotechnology, SAPA facilitates communication among scientists, policy makers, government

officials, educators, and journalists from both the U.S. and China through its interdisciplinary conferences, symposia, section meetings, seminars, workshops, and diverse publications.

The event was well-attended by scientists, entrepreneurs, corporate business development experts, CEOs and investors from the U.S. and Greater China region, including **C-Bridge Capital, Perceptive Advisors, E Squared Asset Management, Share Capital, Northern Light Venture Capital, Qiming Venture Partners, Lilly Asia Ventures, Qilu Pharmaceutical, Turret Capital, Deloitte, McKinsey & Co., Bank of China, 6 Dimensions Capital, Cedrus Investments, Loncar Investments, Sangel Capital, Fosun Pharma, Hengrui Therapeutics, Celgene, IBM Watson Health and Frontage Laboratories.**

Mr. Xiaodong Chen, Ph.D., Executive Vice President of SAPA, said, "Kim did a great job facilitating a well-planned and high-energy discussion that attracted a large audience. We received very positive feedback about Kim's session."

### **About Cedrus Investments**

Cedrus Investments is a global boutique investment firm headquartered in Hong Kong, specializing in Asset Management and Financial Advisory Services. Cedrus has extensive experience and a global network in the life sciences industry together with cross-border transactions track record in geographies, including China, Australia, Asia, U.S., and Europe.

Media Enquiry:

Cedrus Investments Ltd.

Amy Sin

+852-3519-2828

information@cedrusinvestments.com

Logo - <https://photos.prnasia.com/prnh/20150930/8521506461LOGO>

SOURCE Cedrus Investments